Caterina S.
- Country
- Italy
- Department
- UOC Oncologia 1
Research Overview
- A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma patients who have progressed after an approved immune checkpoint inhibitor containing regimen in First-Line HCC
- Evaluation of Sequential Versus Up-Front Administration of Durvalumab, Tremelimumab, and Bevacizumab in Non-Resectable Hepatocellular Carcinoma
Data & Insights
Has run more than one trial at 3 of 27 partner sites.
Specializations
Liver Cancer Research
This investigator specializes in advanced treatments for hepatocellular carcinoma (HCC), with particular focus on non-resectable and metastatic cases. Their research explores innovative therapeutic approaches in liver oncology.
- Advanced Stage HCC Management
- Non-resectable Liver Cancer Treatment
- Metastatic HCC Therapy
Their expertise extends to cases involving Child-Pugh A classification and treatment-resistant conditions.
Immunotherapy Applications
The investigator works extensively with immune checkpoint inhibitor therapies, studying novel combinations of immunotherapeutic agents for liver cancer treatment. Their work includes evaluation of emerging immunotherapy combinations.
- Combination Immunotherapy
- Novel Therapeutic Antibodies
- Sequential Treatment Approaches
Research focuses on optimizing immunotherapy combinations for enhanced treatment outcomes.
Treatment Innovation
The investigator explores multi-modal treatment strategies incorporating targeted therapies and antiangiogenic agents. Their research includes investigation of triple-combination treatments and sequential therapy approaches.
- Triple Combination Protocols
- Second-line Treatment Options
- Treatment Resistance Solutions
Special attention is given to developing solutions for patients who have progressed after first-line treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.